Basic Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Jan 14, 2018; 24(2): 179-194
Published online Jan 14, 2018. doi: 10.3748/wjg.v24.i2.179
Figure 2
Figure 2 Metabolic effects of liraglutide, obeticholic acid, and elafibranor treatment in DIO-nonalcoholic steatohepatitis mice. aP < 0.05, bP < 0.01, cP < 0.001 vs vehicle controls; OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.